Andrea Manubens
Research Subjects
Andrea Manubens has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Bruno Paiva
Cancer Center Clínica Universidad de Navarra (CCUN), Centro de Investigación Médica Aplicada (CIMA LAB Diagnostics), IDISNA, CIBERONC, Pamplona, Spain
1 shared publication - Carmen Gonzalez
Cima Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369, Cancer Center Clínica Universidad de Navarra, Pamplona, Spain
1 shared publication - Jesus Fernando San Miguel
Cancer Center Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra, CIBER-ONC number CB16/12/00369, Pamplona, Spain
1 shared publication - Luis-Esteban Tamariz-Amador
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
1 shared publication - Marta Lasa
Centro de Investigacion Medica Aplicada (CIMA), Universidad de Navarra, 31008 Pamplona, Spain
1 shared publication - Paula Rodríguez-Otero
Cancer Center Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain
1 shared publication
Latest Publications
- 1 September 2026
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 32 (5)
Minimal Residual Disease (MRD) in Multiple Myeloma: From Prognostic Marker to Therapeutic Compass
Multiple myeloma has long been considered incurable; however, advances in therapy have markedly improved outcomes, with a growing proportion of patients achieving sustained remissions suggestive of cure. Minimal (or measurable) residual disease (MRD) has emerged as the most informative biomarker for assessing depth of response and predicting clinical outcomes. Evidence consistently demonstrates that MRD negativity surpasses conventional complete response in prognostic value across disease settings, treatment regimens, and risk groups. Furthermore, MRD has shown potential as a surrogate endpoint for clinical trials and as a tool to guide therapeutic decisions, including treatment intensification, de-escalation, and maintenance strategies. Emerging data also support its relevance in the context of immunotherapy and non–bone marrow-based assessment approaches. Collectively, these findings position MRD as a central component in the evolution toward more precise and individualized management of multiple myeloma.
- 1 September 2026
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 32 (5)
Minimal Residual Disease (MRD) in Multiple Myeloma: From Prognostic Marker to Therapeutic Compass
Multiple myeloma has long been considered incurable; however, advances in therapy have markedly improved outcomes, with a growing proportion of patients achieving sustained remissions suggestive of cure. Minimal (or measurable) residual disease (MRD) has emerged as the most informative biomarker for assessing depth of response and predicting clinical outcomes. Evidence consistently demonstrates that MRD negativity surpasses conventional complete response in prognostic value across disease settings, treatment regimens, and risk groups. Furthermore, MRD has shown potential as a surrogate endpoint for clinical trials and as a tool to guide therapeutic decisions, including treatment intensification, de-escalation, and maintenance strategies. Emerging data also support its relevance in the context of immunotherapy and non–bone marrow-based assessment approaches. Collectively, these findings position MRD as a central component in the evolution toward more precise and individualized management of multiple myeloma.